Chelsea Therapeutics Announces Interim Results and Plans to Modify Study 306 to Focus on Reduction in Falls Associated ...

02/02/11 CHARLOTTE, N.C. -- Chelsea Therapeutics International, Ltd. announces plans to modify Study 306, a Phase III study of NORTHERA in symptomatic neurogenic orthostatic hypotension associated with Parkinson's disease following a futility determination at the planned interim analysis of the study's primary endpoint and an unblinded review of multiple, secondary outcome measures showing dramatic ...

+

-

 

Chelsea Therapeutics Announces Northera Poster Presentations and Symposium on Neurogenic Orthostatic Hypotension at ...

05/02/11 CHARLOTTE, N.C. -- Chelsea Therapeutics International, Ltd. announced that two posters describing the clinical benefit of NORTHERA have been accepted for presentation at the Movement Disorder Society's 15th International Congress of Parkinson's Disease and Movement Disorders June 5-9, 2011 at The Metro Toronto Convention Centre, Toronto, Ontario, Canada.

+

-

 

Chelsea Therapeutics Announces New Data from Northera Phase III Program in Neurogenic Orthostatic Hypotension ...

06/09/11 CHARLOTTE, N.C. -- Chelsea Therapeutics International, Ltd. announced that new data from Phase III trials in symptomatic neurogenic orthostatic hypotension demonstrating the activity and tolerability of NORTHERA , an orally active synthetic precursor of norepinephrine, were presented at the Movement Disorder Society's 15th International Congress of Parkinson's Disease and Movement Disorders in ...

+

-